|Bid||45.50 x 1000|
|Ask||47.80 x 1300|
|Day's Range||46.13 - 49.38|
|52 Week Range||22.22 - 59.00|
|Beta (3Y Monthly)||3.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.35|
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
The legal battle over a method of altering a person’s genes that’s worth billions of dollars escalated this week, with the University of California alleging that the Cambridge-based Broad Institute withheld information in an attempt to deceive U.S. patent officials.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
ZUG, Switzerland and CAMBRIDGE, Mass., July 31, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -24.69% and -97.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110™, targeting.
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
On CNBC's "Mad Money Lightning Round," Jim Cramer said eBay Inc (NASDAQ: EBAY ) is going much higher. He explained that it's splitting up and bringing out value. Cloudera Inc (NYSE: CLDR ) missed ...
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
ZUG, Switzerland and CAMBRIDGE, Mass., July 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
The big shareholder groups in CRISPR Therapeutics AG (NASDAQ:CRSP) have power over the company. Generally speaking, as...
Joining Yahoo Finance's Jen Rogers and Myles Udland is Brian Shannon, CMT and founder of www.alphatrends.net, who breaks down the bullish action in Crispr.